Mostrar el registro sencillo del ítem
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
| dc.contributor.author | Xu, C.-F. | |
| dc.contributor.author | Johnson, T. | |
| dc.contributor.author | García-Donas, J. | |
| dc.contributor.author | Esteban González, Emilio | |
| dc.date.accessioned | 2015-12-21T10:40:09Z | |
| dc.date.available | 2015-12-21T10:40:09Z | |
| dc.date.issued | 2015 | |
| dc.identifier.citation | British Journal of Cancer, 112(7), p. 1190-1198 (2015); doi:10.1038/bjc.2015.64 | |
| dc.identifier.issn | 0007-0920 | |
| dc.identifier.uri | http://hdl.handle.net/10651/34242 | |
| dc.description.sponsorship | This study was funded by GlaxoSmithKline. Pfizer provided funding for the Spanish Oncology Genitourinary Group (SOGUG) sunitinib study. | |
| dc.description.statementofresponsibility | Xu, C.-F., Johnson, T., Garcia-Donas, J., Choueiri, T.K., Sternberg, C.N., Davis, I.D., Bing, N., Deen, K.C., Xue, Z., McCann, L., Esteban, E., Whittaker, J.C., Spraggs, C.F., Rodríguez-Antona, C., Pandite, L.N., Motzer, R.J. | |
| dc.format.extent | p. 1190-1198 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | British Journal of Cancer | |
| dc.rights | © 2015 Cancer Research UK. | |
| dc.rights | CC Reconocimiento - NoComercial - CompartirIgual 4.0 España | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | |
| dc.source | Scopus | |
| dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-84938554756&partnerID=40&md5=146dca94cec1cb4217f56b5381572de9 | |
| dc.title | IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma | |
| dc.type | journal article | |
| dc.identifier.doi | 10.1038/bjc.2015.64 | |
| dc.relation.publisherversion | http://dx.doi.org/10.1038/bjc.2015.64 | |
| dc.rights.accessRights | open access |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
Este ítem está sujeto a una licencia Creative Commons